Background
==========

Non-typhoidal *Salmonella* are one of the leading causes of bacterial foodborne disease in the United States, accounting for over a million human cases each year \[[@B1]\]. Salmonellosis symptoms include diarrhea, fever and abdominal cramps that occur 12 to 72 hours after infection. Annually, *Salmonella* is responsible for an estimated 20,000 hospitalizations and nearly 400 deaths in the United States, with a financial burden of approximately \$3.3 -- 4.4 billion \[[@B2],[@B3]\]. Most infections are transmitted via ingestion of contaminated food and, unlike trends with other bacterial foodborne pathogens, the annual incidence rate of salmonellosis has not significantly declined over the past decade. Since 2006, nearly a fifth of all salmonellosis cases in the United States were caused by *Salmonella enterica* subsp. *enterica* serovars Typhimurium (*S.* Typhimurium) and Heidelberg (*S.* Heidelberg) \[[@B4]\]. According to the Centers for Disease Control and Prevention, there have already been two outbreaks in 2013 where *S.* Typhimurium and *S.* Heidelberg were responsible \[[@B5],[@B6]\].

To limit and reduce the scope of a *Salmonella* outbreak, an efficient and robust surveillance system is vital. During epidemiological investigations *Salmonella* isolates are serotyped and concurrently subtyped to classify isolates to the strain level. An ideal subtyping method has a high discriminatory power (i.e. can separate all unrelated strains) but is not so discriminatory that it inadvertently separates isolates that are part of the same outbreak (i.e. possesses high epidemiologic concordance). There are several molecular-based subtyping approaches that have been developed, including pulsed-field gel electrophoresis (PFGE) \[[@B7]\], amplified fragment length polymorphism (AFLP) \[[@B8]-[@B10]\], multiple-locus variable-number tandem-repeat analysis (MLVA) \[[@B11]-[@B17]\], multiple amplification of prophage locus typing (MAPLT) \[[@B13],[@B18]\] and, most recently, a multiplex DNA suspension array \[[@B19]\]. PFGE was adapted to *Salmonella* in the 1990s and generally provides a high discriminatory power for subtyping most *Salmonella* serovars, though it certainly does not provide equal sensitivity across all serovars \[[@B20]\]. Despite being labor-intensive and time-consuming, conventional serotyping and concurrent PFGE fingerprinting is still considered the gold standard for *Salmonella* subtyping and is widely used by public health surveillance laboratories \[[@B21]-[@B23]\]. Although PFGE data are uploaded to PulseNet USA (<http://www.cdc.gov/pulsenet>), the national electronic network for food disease surveillance that is coordinated by the CDC, inter-laboratory comparisons of PFGE fingerprints can be ambiguous.

There are several different PFGE patterns, or pulsotypes, though most often a limited number of common patterns are associated with the majority of isolates within a given serovar. Two recent *S.* Typhimurium and *S.* Heidelberg foodborne outbreaks in the United States involved contaminated cantaloupe melons (*S.* Typhimurium, 2012; 228 reported illnesses) \[[@B24]\] and broiled chicken livers (*S.* Heidelberg, 2011; 190 reported illnesses) \[[@B25]\]. In both cases, the individual *Xba*I PFGE patterns associated with each strain were fairly common: for *S.* Typhimurium, the associated PFGE pattern is typically seen in 10--15 cases per month \[[@B24]\] and for *S.* Heidelberg, the pattern occurs even more frequently, 30--40 cases per month \[[@B25]\]. Consequently, identification of the outbreak strains was particularly difficult and to more accurately identify isolates that were part of the *S.* Typhimurium cantaloupe outbreak, these isolates were also analyzed by MVLA to define the outbreak strain. Additionally, another *S.* Heidelberg outbreak in 2011, linked to ground turkey, involved isolates with two similar but distinctly different PFGE patterns, thus showing reduced epidemiologic concordance by this subtyping method \[[@B26]\]. This last example may indicate evolutionary relatedness between the two sets of isolates which, unlike some methods, PFGE cannot really provide.

The recent outbreak cases described above highlight the need for additional subtyping approaches for *Salmonella* that can be used instead of, or as a complement to PFGE for routine disease surveillance and outbreak tracking. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) are found in \~50% of all bacterial species, including *Salmonella*\[[@B27]\]. CRISPR elements comprise several unique short sequences, called spacers, which are interspaced by conserved direct repeats. In some bacteria, homology between a spacer and a complementary target nucleic acid results in degradation of the target by sequence-specific endonucleases, providing protection from exogenous bacteriophage or plasmid DNA \[reviewed in \[[@B28]\]. Due to both acquisition and loss of these spacer elements, CRISPRs represent arguably the most rapidly evolving prokaryotic loci \[[@B29]-[@B31]\].

Sequence analysis of CRISPR loci has been used to subtype clinical isolates of *Salmonella*\[[@B32]-[@B34]\], *Escherichia coli*\[[@B35],[@B36]\], group A *Streptococcus*\[[@B37]\] and *Campylobacter* species \[[@B38]\]. *Salmonella* contains two of these non-coding loci, which are comprised of direct repeats of 29 nucleotides separated by spacers of 32 nucleotides (Figure [1](#F1){ref-type="fig"}). Generally, CRISPR polymorphisms between *Salmonella* strains are due to deletion or repetition of one or more spacers, termed 'spacer microevolution' \[[@B32]-[@B34],[@B39],[@B40]\]. An extensive investigation of 738 isolates, representing several different serovars, showed that polymorphisms within the CRISPR loci correlate highly with serovar, with isolates from individual serovars bearing distinct CRISPR patterns \[[@B32]\].

![***Salmonella*CRISPR loci.***Salmonella* have two CRISPR loci, CRISPR1 and CRISPR2 comprised of direct repeats of 29 nucleotides (black diamonds) separated by spacers (empty rectangles). There is an A-T rich leader sequence upstream of each locus (shaded rectangle) and the *C*RISPR-*as*sociated genes (*cas*) are upstream of the CRISPR1 locus (grey boxed arrow). Primers used for amplification are shown in blue and red for CRISPR1 and CRISPR2, respectively.](1471-2180-13-254-1){#F1}

We recently developed a sequence-based subtyping assay (multi-virulence locus sequence typing; MVLST) for *Salmonella* that involves the sequencing of two virulence genes, *fimH1* (*fimH*) and *sseL*, in addition to CRISPR sequencing \[[@B33]\]. Preliminary studies showed that this approach, termed CRISPR-MVLST, provided better discrimination than either CRISPR or MVLST alone and, importantly, exhibited strong epidemiologic concordance among eight out of nine of the most common illness-causing *Salmonella enterica* serovars \[[@B33]\], including both *S.* Heidelberg and *S.* Typhimurium outbreak strains. Subsequently, among a large number of clinical isolates of the highly clonal *S.* Enteritidis, a combination of CRISPR-MVLST and PFGE was required to provide a sufficient discriminatory power \[[@B34]\]. Among a large set of *S.* Newport clinical isolates, CRISPR-MVLST provides similar discrimination to PFGE \[[@B41]\].

To further determine the functionality of this new subtyping approach, we investigated the discriminatory power of both CRISPR-MVLST and PFGE among a larger and unbiased collection of clinical S. Typhimurium and *S.* Heidelberg isolates that were collected over a five year period. We show here that a combination of both CRISPR-MVLST and PFGE is required to achieve an appropriate discriminatory power for *S.* Heidelberg. For *S.* Typhimurium, both subtyping methods independently provide a discriminatory power \>0.94. Importantly, as one of the first applications of CRISPR-MVLST to analyze isolates that were part of an outbreak, we were able to cluster two different *S.* Typhimurium outbreak strains.

Results
=======

Results of CRISPR-MVLST
-----------------------

To more accurately determine the discriminatory power of CRISPR-MVLST and PFGE for *S.* Heidelberg and *S.* Typhimurium, we subtyped 89 and 86 isolates, respectively, that were obtained from the Pennsylvania Department of Health (Table [1](#T1){ref-type="table"}). Among the 175 total isolates analyzed, we identified 29 CRISPR1 alleles, 31 CRISPR2 alleles, 6 *fimH* alleles and 7 *sseL* alleles (Table [2](#T2){ref-type="table"}). Of these, we found 27, 30, 2 and 4 alleles, respectively, that were novel and not seen in our previous data sets \[[@B33]\]. In total, these alleles defined 58 novel sequence types among the two serovars (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). The overwhelming sequence-type diversity among both of these prevalent serovars is provided by genetic variability in the CRISPR loci, rather than in either *fimH* or *sseL* (Figure [2](#F2){ref-type="fig"}). We found that 88/89 *S.* Heidelberg isolates had *fimH* allele 7 and in *S.* Typhimurium there were two predominant *fimH* alleles, allele 6 (52/86 isolates) and allele 8 (28/86 isolates). Similarly, in *S.* Heidelberg, 88/89 isolates bore *sseL* allele 19 and in *S.* Typhimurium, 73/86 isolates had *sseL* allele 15. The polymorphisms between different *sseL* or *fimH* alleles arise from the presence of SNPs with the exception of allele 63 that has a single base insertion. No alleles for any of the four markers were shared among the two different serovars, consistent with previously published studies \[[@B32]-[@B34]\].

###### 

**List of 175*S.*Heidelberg and*S.*Typhimurium isolates from the Pennsylvania Department of Health that were analyzed in this study**

       **Isolate**        **Sequence type**   **PFGE pattern**   **PA region**   **Isolation date**
  ---------------------- ------------------- ------------------ --------------- --------------------
   ***S. Heidelberg***                                                                    
         06E00444               HST 7           JF6X01.0022           SE               Mar-06
         06E00726               HST 7           JF6X01.0022           SE               Jun-06
         06E01437               HST 7           JF6X01.0022           SE               Aug-06
         07E00466               HST 7           JF6X01.0022           SE               Apr-07
         07E00768               HST 7           JF6X01.0022           NC               May-07
         07E01405               HST 7           JF6X01.0022           SE               Aug-07
         07E01505               HST 7           JF6X01.0022           SE               Aug-07
         08E00753               HST 7           JF6X01.0022           NE               Jun-08
         08E01373               HST 7           JF6X01.0022           SE               Aug-08
         09E00637               HST 7           JF6X01.0022           SE               Mar-09
         09E00701               HST 7           JF6X01.0022           SE               Mar-09
         09E00750               HST 7           JF6X01.0022           SE               Apr-09
         09E00782               HST 7           JF6X01.0022           SE               Apr-09
         09E01149               HST 7           JF6X01.0022           SE               May-09
         09E01511               HST 7           JF6X01.0022           SE               Jun-09
      M09019838001A             HST 7           JF6X01.0022           SE               Aug-09
      M10003150001A             HST 7           JF6X01.0022           SE               Jan-10
      M10014816001A             HST 7           JF6X01.0022           SE               Jun-10
      M10016406001A             HST 7           JF6X01.0022           SE               Jul-10
      M10022189001A             HST 7           JF6X01.0022           SE               Sep-10
      M11012103001A             HST 7           JF6X01.0022           SW               Apr-11
      M11017212001A             HST 7           JF6X01.0022           SE               Jul-11
      M11021620001A             HST 7           JF6X01.0022           SW               Aug-11
         06E00846               HST 7           JF6X01.0032           SW               Jun-06
         08E00963               HST 7           JF6X01.0033           SW               Jul-08
         08E01089               HST 7           JF6X01.0033           SE               Jul-08
         07E01378               HST 7           JF6X01.0034           SW               Jul-07
         08E00470               HST 7           JF6X01.0034           NE               May-08
         08E00508               HST 7           JF6X01.0034           NE               May-08
      M10000626001A             HST 7           JF6X01.0034           SW               Dec-09
         07E00964               HST 7           JF6X01.0042           NW               Jun-07
      M11025202001A             HST 7           JF6X01.0042           SC               Oct-11
      M11027881001A             HST 7           JF6X01.0042           NE               Nov-11
         07E01870               HST 7           JF6X01.0045           SC               Sep-07
      M09021251001A             HST 7           JF6X01.0051           SE               Sep-09
         09E00927               HST 7           JF6X01.0058           SE               May-09
         08E00342               HST 7           JF6X01.0080           SE               Mar-08
      M11018110001A             HST 7           JF6X01.0087           NW               Jul-11
         06E00558               HST 7           JF6X01.0122           NW                  
         07E00680               HST 7           JF6X01.0122           SW               May-07
         07E02336               HST 7           JF6X01.0161           SW               Nov-07
         07E02139               HST 7           JF6X01.0167           SW               Oct-07
      M09033280001A             HST 7           JF6X01.0221           SE               Dec-09
      M10004098001A             HST 7           JF6X01.0246           SE               Feb-10
         08E01461               HST 7           JF6X01.0324           SE               Aug-08
         09E00128               HST 7           JF6X01.0324           SE               Jan-09
      M09015668001A             HST 7           JF6X01.0326           SE               Jul-09
      M10015955001A             HST 7           JF6X01.0581           SW               Jul-10
         06E01523               HST 8           JF6X01.0051           SE               Sep-06
         08E00143               HST 9           JF6X01.0022           NE               Feb-13
         08E01679               HST 9           JF6X01.0022           SC               Sep-08
         06E01915               HST 9           JF6X01.0022           SC               Oct-06
         07E00349               HST 9           JF6X01.0022           SW               Feb-07
         07E02366               HST 9           JF6X01.0022           NE               Dec-07
         09E01408               HST 9           JF6X01.0022           SW               Jun-09
      M10006052001A             HST 9           JF6X01.0022           SW               Mar-10
      M10021328001A             HST 9           JF6X01.0022           SC               Sep-10
      M11000821001A             HST 9           JF6X01.0041           NW               Jan-11
         06E00519               HST 9           JF6X01.0052           NE               Apr-06
         07E00933              HST 10           JF6X01.0051           SC               Jun-07
         08E00107              HST 11           JF6X01.0085           NE               Jan-08
         09E00226              HST 12           JF6X01.0022           SE               Jan-09
      M10020282001A            HST 13           JF6X01.0034           NC               Sep-10
         07E02483              HST 14           JF6X01.0022           SC               Dec-07
         08E00103              HST 14           JF6X01.0022           SE               Jan-08
         07E00451              HST 15           JF6X01.0049           SC               Mar-07
         08E01904              HST 15           JF6X01.0049           SW               Sep-08
         08E01911              HST 15           JF6X01.0049           SW               Oct-08
         07E01400              HST 16           JF6X01.0270           SE               Jul-07
      M10004892001A            HST 17           JF6X01.0041           SE               Mar-10
      M11005464001A            HST 17           JF6X01.0041           SW               Feb-11
      M11000267001A            HST 17           JF6X01.0500           NW               Dec-10
      M09020244001A            HST 18           JF6X01.0321           SW               Aug-09
      M09022904001A            HST 19           JF6X01.0022           NE               Sep-09
      M11020321001A            HST 20           JF6X01.0042           SE               Aug-11
      M10018092001A            HST 21           JF6X01.0033           SW               Aug-10
      M11011342001A            HST 21           JF6X01.0058           SW               Apr-11
      M11013202001A            HST 21           JF6X01.0058           SW               May-11
      M11015845001A            HST 21           JF6X01.0058           SW               Jun-11
      M11015850001A            HST 21           JF6X01.0058           SW               Jun-11
      M11023722001A            HST 21           JF6X01.0058           SW               Sep-11
      M11005685001A            HST 21           JF6X01.0582           SW               Feb-11
      M10002453001A            HST 22           JF6X01.0032           SC               Jan-10
      M09016444001A            HST 22           JF6X01.0033           NC               Jul-09
         07E02184              HST 23           JF6X01.0042           SE               Oct-07
         07E01907              HST 24           JF6X01.0058           SW               Sep-07
         06E00416              HST 25           JF6X01.0172           NC               Mar-06
         06E00661              HST 26           JF6X01.0022           SE               Jun-06
         06E01299              HST 27           JF6X01.0022           SE               Aug-06
   ***S. Typhimurium***                                                                   
         07E00002               TST 9           JPXX01.0177                            Dec-06
         07E02276               TST 9           JPXX01.0177                            Nov-07
         08E02063               TST 9           JPXX01.0177                            Oct-08
         09E00003               TST 9           JPXX01.0177                            Dec-08
      M09023403001A             TST 9           JPXX01.0177                            Sep-09
         07E01490              TST 10           JPXX01.0003                            Aug-07
         07E01769              TST 10           JPXX01.0003                            Sep-07
         07E02403              TST 10           JPXX01.0003                            Dec-07
         08E00363              TST 10           JPXX01.0003                            Apr-08
         09E00309              TST 10           JPXX01.0003                            Jan-09
      M10005050001A            TST 10           JPXX01.0003                            Feb-10
      M10010138001A            TST 10           JPXX01.0003                            Apr-10
      M10023515001A            TST 10           JPXX01.0003                            Oct-10
         07E00173              TST 10           JPXX01.0018                            Jan-07
         08E00006              TST 10           JPXX01.0018                            Dec-07
      M09017753001A            TST 10           JPXX01.0018                            Jul-09
      M10003149001A            TST 10           JPXX01.0018                            Jan-10
      M10006054001A            TST 10           JPXX01.0098                            Mar-10
         07E00658              TST 10           JPXX01.0256                            Apr-07
         08E00457              TST 10           JPXX01.1011                            Apr-08
      M10018865001A            TST 10           JPXX01.2731                            Aug-10
         07E00234              TST 11           JPXX01.0442                            Feb-07
      M10001003001A            TST 11           JPXX01.0442                            Jan-10
         07E00290              TST 12           JPXX01.0022                            Feb-07
         07E00436              TST 12           JPXX01.0146                            Mar-07
      M09028540001A            TST 12           JPXX01.0146                            Oct-09
      M10012000001A            TST 12           JPXX01.0146                            May-10
      M11018826001A            TST 12           JPXX01.0604                            Jul-11
         09E01310              TST 12           JPXX01.0925                            May-09
         08E02215              TST 12           JPXX01.1302                            Nov-08
         08E00255              TST 13           JPXX01.0001                            Feb-08
      M11021986001A            TST 13           JPXX01.0081                            Aug-11
         09E00084              TST 13           JPXX01.0111                            Dec-08
         07E00868              TST 13           JPXX01.0206                            Jun-07
         07E00568              TST 13           JPXX01.0642                            Apr-07
         07E00364              TST 13           JPXX01.1212                            Jan-07
         07E01042              TST 14           JPXX01.1393                            Jun-07
         07E01180              TST 15           JPXX01.0003                            Jun-07
         08E01211              TST 15           JPXX01.0003                            Jul-08
      M11004438001A            TST 15           JPXX01.0003                            Jan-11
      M11016520001A            TST 15           JPXX01.0070                            Jun-11
         07E01365              TST 16           JPXX01.0928                            Jul-07
         08E00877              TST 17           JPXX01.0006                            Jun-08
         08E01423              TST 17           JPXX01.0006                            Aug-08
         07E02063              TST 17           JPXX01.0146                            Oct-07
      M09025088001A            TST 17           JPXX01.0146                            Oct-09
      M11002975001A            TST 17           JPXX01.0146                            Jan-11
         08E01686              TST 17           JPXX01.0416                            Sep-08
         07E02348              TST 18           JPXX01.0018                            Nov-07
         08E00618              TST 19           JPXX01.0146                            May-08
      M10000110001A            TST 19           JPXX01.0146                            Jan-10
      M10010755001A            TST 19           JPXX01.0146                            May-10
      M11025544001A            TST 19           JPXX01.0146                            Sep-11
         08E00074              TST 19           JPXX01.0557                            Jan-08
      M11011894001A            TST 19           JPXX01.2900                            Apr-11
      M09018928001A            TST 20           JPXX01.0001                            Aug-09
         08E00162              TST 20           JPXX01.0014                            Feb-08
         09E00747              TST 20           JPXX01.0014                            Apr-09
      M11029619001A            TST 20           JPXX01.0014                            Nov-11
      M10026894001A            TST 20           JPXX01.0146                            Nov-10
         08E00998              TST 21           JPXX01.0604                            Jul-08
         08E02429              TST 22           JPXX01.1396                            Dec-08
         09E00422              TST 23           JPXX01.1255                            Feb-09
         09E00632              TST 24           JPXX01.1975                            Mar-09
         09E00904              TST 25           JPXX01.2016                            Apr-09
      M09014919001A            TST 26           JPXX01.0083                            Jun-09
      M09015997001A            TST 27           JPXX01.0416                            Jul-09
      M09020496001A            TST 28           JPXX01.0146                            Aug-09
      M09021700001A            TST 29           JPXX01.0552                            Sep-09
      M10014370001A            TST 30           JPXX01.0333                            Jun-10
      M10015309001A            TST 31           JPXX01.0003                            Jun-10
      M10016817001A            TST 32           JPXX01.0324                            Jul-10
      M10025067001A            TST 33           JPXX01.0359                            Oct-10
      M10028492001A            TST 34           JPXX01.0060                            Dec-10
      M11001607001A            TST 35           JPXX01.0359                            Jan-11
      M11009301001A            TST 36           JPXX01.1678                            Mar-11
      M11012744001A            TST 37           JPXX01.0013                            May-11
      M11015184001A            TST 38           JPXX01.1833                            Jun-11
      M11022803001A            TST 39           JPXX01.0146                            Sep-11
      M10007760001A            TST 40           JPXX01.2488                            Apr-10
      M11006620001A            TST 41           JPXX01.1314                            Feb-11
      M11024498001A            TST 42           JPXX01.0351                            Oct-11
         09E01078              TST 42           JPXX01.0781                            May-09
         07E00784              TST 56           JPXX01.0359                            May-07
         08E00321              TST 57           JPXX01.1301                            Mar-08
      M09031352001A            TST 58           JPXX01.0146                            Nov-09

The data are shown in order of Sequence Type (HST or TST) and further sorted by PFGE pattern.

###### 

Number of alleles identified for each of the four CRISPR-MVLST markers

     **Serovar**      ***fimH***   ***sseL***   **CRISPR1**   **CRISPR2**
  ------------------ ------------ ------------ ------------- -------------
   *S.* Heidelberg      0 (2)        1 (2)        12 (12)        7 (8)
   *S.* Typhimurium     2 (4)        3 (5)        13 (15)       19 (19)
        Total           2 (6)        4 (7)        25 (27)       26 (27)

The total number of alleles for each locus is listed in parentheses with the number of alleles that are new in this study, as compared to Liu et al. \[[@B33]\], shown to the left.

###### 

**List of all*S. H*eidelberg CRISPR-MVLST*S*equence*T*ypes (HSTs) that were identified in this study**

   **HST**   **Frequency**   **Allelic profile**             
  --------- --------------- --------------------- ---- ----- -----
    HST 7        *48*                17            19   167   32
    HST 8         *1*                17            19   168   209
    HST 9        *10*                17            19   167   209
   HST 10         *1*                17            19   169   32
   HST 11         *1*                17            19   170   32
   HST 12         *1*                17            19   171   32
   HST 13         *1*                18            19   167   32
   HST 14         *2*                17            19   179   32
   HST 15         *3*                17            19   167   212
   HST 16         *1*                17            19   173   213
   HST 17         *3*                17            19   172   32
   HST 18         *1*                17            19   178   32
   HST 19         *1*                17            67   174   209
   HST 20         *1*                17            19   175   32
   HST 21         *7*                17            19   167   211
   HST 22         *2*                17            19   167   210
   HST 23         *1*                17            19   177   32
   HST 24         *1*                17            19   167   214
   HST 25         *1*                17            19   176   32
   HST 26         *1*                17            19   177   215
   HST 27         *1*                17            19   167   215

The numbers represent the allelic identifier for the individual CRISPR-MVLST markers. The combination of four specific alleles defines a given HST. The frequency is the number of times a particular HST was observed among the 89 *S.* Heidelberg isolates analyzed. All HSTs identified here were new and not seen in previous studies.

###### 

**List of all*S. T*yphiurium CRISPR-MVLST*S*equence*T*ypes (TSTs) that were identified in this study**

   **TST**   **Frequency**   **Allelic profile**             
  --------- --------------- --------------------- ---- ----- ---------
    TST 9         *5*                 6            15   129    159\*
   TST 10        *16*                 8            15   11      160
   TST 11         *2*                 6            15   10     163\*
   TST 12         *7*                 6            15   10     164\*
   TST 13         *6*                 6            15   129     162
   TST 14         *1*                 6            15   129     165
   TST 15         *4*                 8            15   11      161
   TST 16         *1*                 8            61   11      160
   TST 17         *6*                 6            15   10     167\*
   TST 18         *1*                 8            20   131     160
   TST 19         *6*                 6            62   10     164\*
   TST 20         *5*                49            15   129     162
   TST 21         *1*                 6            15   132    164\*
   TST 22         *1*                 6            15   10     168\*
   TST 23         *1*                 8            20   11      160
   TST 24         *1*                 6            15   133    167\*
   TST 25         *1*                50            20   134    169\*
   TST 26         *1*                 6            15   10     170\*
   TST 27         *1*                 6            15   10     171\*
   TST 28         *1*                 6            15   10     172\*
   TST 29         *1*                 8            62   11      160
   TST 30         *1*                 6            15   137     174
   TST 31         *1*                 8            15   11      175
   TST 32         *1*                 6            15   135     162
   TST 33         *1*                 6            15   138    177\*
   TST 34         *1*                 8            15   139     161
   TST 35         *1*                 6            15   140    178\*
   TST 36         *1*                 8            63   11      160
   TST 37         *1*                 6            15   141     162
   TST 38         *1*                 6            15   10     179\*
   TST 39         *1*                 6            15   10     180\*
   TST 40         *1*                 6            15   142    173\*
   TST 41         *1*                 8            20   143     166
   TST 42         *2*                 6            15   10    181\*\*
   TST 56         *1*                 6            15   130    173\*
   TST 57         *1*                 6            15   10    205\*\*
   TST 58         *1*                 6            15   136    164\*
   TST 59         \-                  6            62   10     207\*
   TST 60         \-                  6            15   166    208\*

The numbers represent the allelic identifier for the individual CRISPR-MVLST markers. The combination of four specific alleles defines a given HST. The frequency is the number of times a particular TST was observed among the 86 *S.* Typhimurium isolates analyzed in the first study and does not include the frequency of TSTs that were seen in the outbreak study. All TSTs identified here were new and not seen in previous studies. ^a^Some CRISPR2 alleles required more than two sequencing primers to cover the whole length of the array. Alleles that required three primers are noted with \* and the two isolates that required seven primers to sequence CRISPR2 are noted with \*\*. The position of these primers is shown in Additional file [1](#S1){ref-type="supplementary-material"}.

![**Contribution of allele number for each marker.** Pie charts showing the combined total number of different alleles identified at all four loci. The contribution of each marker to this total is shown for **a)** combined all alleles from both *S.* Heidelberg and *S.* Typhimurium, **b)***S.* Heidelberg and **c)***S.* Typhimurium. F -- *fimH*; S -- *sseL*.](1471-2180-13-254-2){#F2}

*S*. Heidelberg analysis and sequence type distribution
-------------------------------------------------------

CRISPR-MVLST analysis of 89 *S*. Heidelberg clinical isolates (representing 27 unique PFGE patterns) resulted in 21 unique *S. H*eidelberg *S*equence *T*ypes (HSTs), HST 7 -- HST 27 (Table [3](#T3){ref-type="table"}). In total, we identified 12 CRISPR1 alleles, 8 CRISPR2 alleles, 2 *fimH* alleles and 2 *sseL* alleles (Table [2](#T2){ref-type="table"}). As shown in Figure [2](#F2){ref-type="fig"}b, most of the allelic diversity comes from the CRISPR1 and CRISPR2 loci. All 12 CRISPR1 alleles and seven of the eight CRISPR2 alleles were new, compared to our previous studies \[[@B33]\]. We did not find any new *fimH* alleles in our dataset and only one of the two *sseL* alleles was new. The most frequent ST was HST7, occurring in 49/89 isolates (54%).

Discriminatory power of CRISPR-MVLST and PFGE in *S.* Heidelberg isolates
-------------------------------------------------------------------------

The discriminatory power of CRISPR-MVLST among the *S.* Heidelberg isolates was calculated to be 0.6931 (Figure [3](#F3){ref-type="fig"}a). The discriminatory power provided by PFGE among the same isolates was 0.8149 (Figure [3](#F3){ref-type="fig"}b). Given these low values and insufficient discriminatory power (an ideal discriminatory power is \>0.95) \[[@B42]\], we combined the two typing methods. This combination provided 44 unique groups with a more satisfactory discriminatory power of 0.9213 (Figure [3](#F3){ref-type="fig"}c), suggesting a 92% confidence in ability to separate unrelated isolates.

![**Frequency of*S.*Heidelberg subtype prevalence generated by CRISPR-MVLST and PFGE.** Pie charts showing the number and frequency of distinct subtypes defined by **a)** CRISPR-MVLST, **b)** PFGE and **c)** the combination of CRISPR-MVLST and PFGE among 89 *S.* Heidelberg isolates. The most frequent subtypes for each method are indicated; .0022 and .0058 represent PFGE profiles JF6X01.0022 and JF6X01.0058, respectively. The number of distinct subtypes defined by each method is listed in parenthesis and the discriminatory power (D) is listed below. **d)** CRISPR-MVLST is able to separate the most common *S.* Heidelberg PFGE pattern JF6X01.0022 into 7 distinct sequence types.](1471-2180-13-254-3){#F3}

Separation of common *S*. Heidelberg subtypes
---------------------------------------------

Among the *S.* Heidelberg isolates analyzed, the most frequent PFGE pulsotype was JF6X01.0022 (42%). We were able to further subtype isolates with JF6X01.0022 pattern into 7 distinct HSTs - HST 7, 9, 12, 14, 19, 26 and 27 (Figure [3](#F3){ref-type="fig"}d). Among JF6X01.0022 isolates, the two most common HSTs were HST7 (62%) and HST9 (22%). JF6X01.0058 is also fairly common, occurring in 8% of isolates studied. With these isolates, we were able to further subtype them into 3 distinct HSTs -- HST 7, 21 and 24, with HST21 being the most common (71%). Conversely, over half the isolates analyzed have HST 7 (54%), but by PFGE analysis, these are represented by 18 different PFGE patterns, the most frequent being JF6X01.0022 (48%). Collectively, this data highlights the strengths and weakness of each subtyping method.

*S.* Typhimurium analysis and sequence type distribution
--------------------------------------------------------

CRISPR-MVLST analysis of 86 *S*. Typhimurium clinical isolates (representing 45 unique PFGE patterns) resulted in the identification of 37 unique and novel *S. T*yphimurium *S*equence *T*ypes (TSTs), TST9 -- TST41, and TST56 -- TST58 (Table [4](#T4){ref-type="table"}). This included 17 CRISPR1, 23 CRISPR2, 4 *fimH* and 5 *sseL* alleles (Table [2](#T2){ref-type="table"}). Of these, the majority of CRISPR1 alleles were new (15/17 alleles) and all CRISPR2 alleles were new (23/23), as compared to our previous studies \[[@B33]\]. As with *S.* Heidelberg, the majority of unique sequence types were defined by polymorphisms in either or both of the CRISPR loci (Figure [2](#F2){ref-type="fig"}c).

Discriminatory power of CRISPR-MVLST and PFGE in *S*. Typhimurium isolates
--------------------------------------------------------------------------

The discriminatory power of CRISPR-MVLST among the *S.* Typhimurium isolates was 0.9415 (Figure [4](#F4){ref-type="fig"}a). This means that there would be a 94% probability that two unrelated isolates could be separated using the CRISPR-MVLST scheme. Similarly, for PFGE, the discriminatory power among these isolates is 0.9486 (Figure [4](#F4){ref-type="fig"}b). These values suggest that either method can provide sufficient discrimination between outbreak and non-outbreak *S.* Typhimurium strains.

![**Frequency of*S.*Typhimurium subtype prevalence generated by CRISPR-MVLST and PFGE.** Pie charts showing the number of distinct subtypes defined by **a)** CRISPR-MVLST and **b)** PFGE among 86 *S.* Typhimurium isolates. The most frequent TSTs or PFGE patterns observed are indicated. .0003 and .0146 represent PFGE profiles JPXX01.0003 and JPXX01.0146, respectively. The number of distinct subtypes defined by each method is listed in parenthesis and the discriminatory power (D) is listed below.](1471-2180-13-254-4){#F4}

Correlation between different TSTs and PFGE patterns
----------------------------------------------------

We next wanted to investigate whether any correlation existed between TSTs and PFGE patterns. To accomplish this, we first determined the relationship among different TSTs. BURST analysis of all 37 TSTs generated four groups (Figure [5](#F5){ref-type="fig"}a). Of these, Groups 1--3 contain 6 -- 15 TSTs. Group 4 consists of only two TSTs and BURST was unable to assign a core TST. There was also a collection of five singletons that BURST did not assign to a group. For Groups 1--3, each group comprises a core TST surrounded by TSTs that differ from the core by one allele. The number of rings in the group demonstrates the number of allele differences from the core. For example, in Group 1 TSTs 9, 37, 32, 20, and 14 each differ by one allele at one locus from the core TST, TST 13. For group 3, TST 10 is the core TST and TSTs 15, 31, 36, 29, 23 and 16 each differ from TST 10 at one locus. TST 34, in the outer ring differs from the TSTs in the middle ring at one locus and from the core at two loci.

![**Correlation of CRISPR-MVLST and PFGE. a)** BURST analysis of 37 TSTs identified in this study shows the relationship between different TSTs. Within a BURST group, the TSTs within one ring differ from TSTs in an adjacent ring at one of the four CRISPR-MVLST loci. TSTs that could not be assigned to a group are listed as singletons. Individual PFGE patterns that are found in isolates that have different TSTs are shown in color and the PFGE pulsotype is indicated as the numbers after JPXX01, i.e. JPXX01.0604 is shown as .0604. **b)** Dendrogram showing the levels of similarity between the 45 different PFGE patterns identified. All the PFGE patterns that are found in isolates with TSTs in Groups 1--3 are shaded in the corresponding color. The blue asterix represents TST 20, which is in Group 1.](1471-2180-13-254-5){#F5}

To investigate whether there was any relationship between CRISPR-MVLST sequence type and PFGE patterns, we overlaid our PFGE data to identify isolates from different TSTs that have the same PFGE pattern. Figure [5](#F5){ref-type="fig"}a shows that there were seven PFGE pulsotypes that could be further separated into TSTs. In the majority of instances (5/7), identical PFGE patterns were found in isolates that had closely related TSTs such as JPXX01.0003 and JPXX01.0604 (TSTs 15, 31, 10 and TSTs 12 and 21, respectively).

Following this, we then generated a dendrogram using the Dice coefficient to determine the relationship between different PFGE pulsotypes. For clarity, we color-coded the PFGE patterns according to the BURST Group shown in Figure [5](#F5){ref-type="fig"}a. As can be seen in Figure [5](#F5){ref-type="fig"}b, closely related CRISPR-MVLST sequence types have similar PFGE patterns.

CRISPR-MVLST analysis of *S*. Typhimurium outbreak isolates
-----------------------------------------------------------

Since CRISPR-MVLST and PFGE exhibit a similarly high discriminatory ability in *S.* Typhimurium, we wanted to investigate the utility of the former for separating outbreak isolates. We obtained 30 *S.* Typhimurium isolates from the Pennsylvania Department of Health (Table [5](#T5){ref-type="table"}). Ten of these were isolates associated with an outbreak in 2004 with the cluster designation 0411PAJPX-1c. All affected persons were on a bus trip together, though the outbreak source was never identified. The remaining 20 isolates comprised 10 isolates that were linked to a 2009 live poultry outbreak (cluster 0905PAJPX-1) and 10 control isolates that were isolated in the same year but were not part of any classified outbreaks.

###### 

**List of 30*S.*Typhimurium isolates used in the outbreak study**

  **Isolate**      **Sequence type**   **PFGE-pattern (*Xba*I)**   **PFGE pattern (*Bln*I)**   **Outbreak cluster**
  --------------- ------------------- --------------------------- --------------------------- ----------------------
  04E02240              TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04E02241              TST 59                JPXX01.0146               **JPXA26.0294**            0411PAJPX-1c
  04E02243              TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04E02295              TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04E02296              TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04E02297              TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04 F00368             TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04 F00376             TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04 F00381             TST 59                JPXX01.0146                 JPXA26.0172              0411PAJPX-1c
  04E02239              TST 59              **JPXX01.0279**               JPXA26.0172              0411PAJPX-1c
  09E00857              TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  09E01235              TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  09E01308              TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  09E01333              TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  09E01424              TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  09E01666              TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  M09015209001A         TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  M09017319001A         TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  M09019457001A         TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  M09021164001A         TST 42                JPXX01.0302                 JPXA26.0183              0905PAJPX-1
  M09015294001A       **TST 42**              JPXX01.0047                    **-**                    **-**
  M09019934001A       **TST 42**              JPXX01.0781                    **-**                    **-**
  M09015723001A         TST 12                JPXX01.0604                 JPXA26.0292                 **-**
  M09019606001A         TST 12                JPXX01.0604                 JPXA26.0174                 **-**
  M09016911001A         TST 12                JPXX01.1214                    **-**                    **-**
  09E00951              TST 13                JPXX01.0001                 JPXA26.0530                 **-**
  M09019186001A         TST 13                JPXX01.0946                    **-**                    **-**
  09E01471              TST 15                JPXX01.2095                    **-**                    **-**
  M09016893001A         TST 19                JPXX01.0146                 JPXA26.0291                 **-**
  M09017200001A         TST 60                JPXX01.0359                    **-**                    **-**

The 10 isolates without cluster information represent the sporadic, or non-outbreak related, isolates used as controls in the study.

CRISPR-MVLST was able to separate the 2004 isolates, with each isolate bearing the unique TST59 (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). These isolates were also analyzed by two-enzyme PFGE, using *Xba*I and *Bln*I. Though they had the same TST, two of the isolates, 04E02241 and 04E02239 had different PFGE patterns with *Bln*I or *Xba*I, respectively, and are indicated in bold in Table [5](#T5){ref-type="table"}. This example shows that CRISPR-MVLST provides an epidemiologic concordance of 1 (E = 1.0) and for PFGE it is less than 1 (E \< 1.0). Additionally, the *Xba*I PFGE pattern associated with this strain, JPXX01.0146, occurred fairly frequently in our initial data set; 12/86 isolates had this pulsotype and we were able to separate these into seven different TSTs.

For the 2009 outbreak isolates, CRISPR-MVLST correctly identified the 10 outbreak isolates (TST42) and these all have the same PFGE pattern, JPXX01.0302, thus for both subtyping methods E = 1.0. Two of the sporadic case control isolates were also TST42 (shown in bold in Table [5](#T5){ref-type="table"}) but these had different PFGE pulsotypes from the outbreak strain, suggesting a lack of discrimination by CRISPR-MVLST in this instance. TST42 was seen in two isolates in the initial study of 86 *S.* Typhimurium isolates. All isolates within each outbreak were identified using CRISPR-MVLST, thus obtaining perfect epidemiological concordance with this subtyping method.

Discussion
==========

Foodborne illness caused by *Salmonella enterica* species, particularly by *S.* Typhimurium and *S.* Heidelberg, accounts for 18.5% of salmonellosis annually in the United States \[[@B4]\]. For accurate outbreak tracking and routine disease surveillance, it is critical that we employ rapid, efficient and robust subtyping methodologies. PFGE is the current gold standard for molecular subtyping of *Salmonella* and other methods include AFLP, MVLA and CRISPR-MVLST.

CRISPR sequence analysis is one of the cheaper and faster methods for *Salmonella* subtyping \[[@B22]\]. For the majority of isolates analyzed, CRISPR-MVLST could be completed in less than 24 hours, including DNA isolation and analysis. Additionally, by virtue of their nature, sequencing data are more robust and tractable; this type of data is unequivocal and, with regards to inter-laboratory or database use, is highly consistent. They also provide increased downstream utilities that involve analysis of sequence information, such as phylogenetic studies. This approach is also in line with other high-throughput subtyping approaches, including real-time CRISPR analysis \[[@B32]\] and whole genome sequence analysis \[[@B43]-[@B47]\]. Conversely, although protocols exist that allow PFGE to be completed in 24 hours, it can often take 1--3 days, requires skilled personnel, inter-laboratory data analysis can be challenging and the data have no utility beyond subtyping. Given the advancement of whole-genome sequencing technologies, typing methods based on these are in development \[[@B48]\]. While highly discriminatory, limitations to this approach that are not issues with either CRISPR-MVLST or PFGE include the time required for analysis and space required for data storage.

CRISPR spacer analysis alone has been used to analyze several different *Salmonella* serovars \[[@B32]\]. Fabre and colleagues showed that among 50 isolates of *S.* Typhimurium and its I,4, \[[@B5]\],12:i- variant, combined CRISPR1 and CRISPR2 sequence information is comparable to PFGE (D = 0.88 and 0.87, respectively). Both methods were more discriminatory than phage typing analysis of the same set of isolates. The same study also analyzed spacer content of *S.* Typhimurium and *S.* Enteritidis from 10 outbreaks and in all cases CRISPR sequences exhibited high epidemiologic concordance.

A preliminary investigation showed that addition of CRISPR spacer analysis to an MVLST scheme improves discrimination, beyond that provided by either approach independently, in eight out of nine of the most common illness-causing *Salmonella* serovars \[[@B33]\]. We wanted to extend our evaluation of CRISPR-MVLST utility among predominant and clinically relevant *Salmonella* serovars. To date we have tested and compared CRISPR-MVLST to PFGE on large numbers of *S.* Enteritidis \[[@B34]\], *S.* Newport \[[@B41]\]*S*, Heidelberg and *S*. Typhimurium isolates. Among the total 175 isolates analyzed here, we found significantly fewer alleles of *fimH* and *sseL*, compared to alleles of either CRISPR locus (Table [2](#T2){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). Given the reduced contribution of the virulence genes to defining STs, their addition may seem superfluous within this subtyping scheme. However, in this data set, *fimH* alleles define two STs, HST13 and TST20 and *sseL* alleles define five STs, TST16, TST19, TST23, TST29 and TST36. This further supports earlier findings showing that addition of MVLST to a CRISPR-based subtyping scheme increases discrimination in *S.* Enteritidis \[[@B34]\] as well as among a broad set of *Salmonella enterica* serovars \[[@B33]\].

Though the number of isolates for each serovar was similar, the number of STs within each serovar is surprisingly disparate: among 89 *S.* Heidelberg isolates we identified 21 HSTs and in 86 *S.* Typhimurium isolates, we identified 37 TSTs. This presumably reflects varied levels of clonality in different serovars. Independently of the number of STs defined for either serovar, the CRISPR loci are responsible for the vast majority of alleles: (*S.* Heidelberg -- 83.3% and *S.* Typhimurium -- 80%) (Figure [2](#F2){ref-type="fig"}). In *S.* Heidelberg, 50% of the different alleles identified were CRISPR1 alleles. Given that CRISPRs are of one of the more dynamic loci in bacteria \[[@B30],[@B31]\], this finding is not unexpected.

Although PFGE was more discriminatory than CRISPR-MVLST among 89 *S.* Heidelberg isolates (D = 0.81 versus 0.69, respectively), a combination of both techniques provided an improved value of 0.92. This represents a 92% probability that two unrelated strains can be separated. JF6X01.0022 is the most common PFGE pattern in PulseNet for *S.* Heidelberg \[[@B49]\] and is seen 30--40 times a month by the CDC. In our data set, 42% of the isolates have the JF6X01.0022 pattern and using CRISPR-MVLST, we were able to further separate these into seven distinct CRISPR-MVLST types (Figure [3](#F3){ref-type="fig"}b and d). Given the frequency at which this PFGE pattern occurs nationally, not all isolates that have this pattern may be associated with a specific outbreak, further enhancing the utility of CRISPR-MVLST as a complement to PFGE analysis. Collectively, these findings in *S.* Heidelberg show that the JF6X01.0022 pattern is analogous to the JEGX01.0004 pattern in *S.* Enteritidis, where the latter was observed in 51% of isolates analyzed and was separated into 12 distinct STs \[[@B34]\]. A proposed improvement for discrimination in *S.* Heidelberg and *S.* Enteritidis by PFGE is to increase the number of enzymes used for PFGE analysis \[[@B50],[@B51]\], though the concurrent use of PFGE and CRISPR-MVLST would be much more efficient than this approach.

Regarding *S.* Heidelberg, our data are similar to that observed in a broad set of *S.* Enteritidis isolates \[[@B34]\]: both serovars exhibit fewer number of STs identified and both require combining CRISPR-MVLST and PFGE to obtain a sufficient discriminatory power. This presumably reflects similar levels of clonality in *S.* Heidelberg and *S.* Enteritidis as compared to more heterogenous serovars such as *S.* Typhimurium where we observed many more STs present within a similar number of isolates examined.

Our data show that in *S.* Typhimurium, the discrimination provided by either PFGE or CRISPR-MVLST is similar (0.9486 versus 0.9415, respectively). When CRISPR-MVLST was applied to outbreak isolates, we were able to correctly identify the 20 isolates representing the two outbreaks, showing an extremely good epidemiologic concordance with this typing method. The epidemiologic concordance was better by CRISPR-MVLST than PFGE in identifying isolates from the 2004 bus trip outbreak and both methods had equal epidemiological concordance for the 2009 live poultry outbreak. Regarding the 2004 outbreak, the majority of isolates had the JPXX01.0146 pulsotype. In our initial study, this pulsotype was seen frequently, 16% of all isolates analyzed, and the 14 isolates with this pattern could also be represented by 7 distinct TSTs. Conversely, all isolates from this outbreak have TST59, which is unique and not seen in our initial data set showing that in this instance, CRISPR-MVLST may be a better subtyping approach. In analyzing the 2009 live poultry outbreak, it appears that PFGE is more discriminatory than CRISPR-MVLST, as CRISPR-MVLST also identified two non-outbreak related isolates as TST42. Given the available epidemiological data available, these two isolates do not appear to be associated with the outbreak. The fact that CRISPR-MVLST works better in some instances than others is not surprising and can also occur when other subtyping methods are used. 'Problematic' PFGE pulsotypes also exist and is one reason that second generation methods like MLVA and CRISPR-MVLST are being developed \[[@B33],[@B52]\]. As a recent example, isolates associated with the 2012 *S.* Typhimurium cantaloupe outbreak, had a common PFGE pattern so additional subtyping by MLVA was performed to correctly define the outbreak strain \[[@B24]\]. That there is a strong association among closely related sequence types and closely related PFGE patterns for both *S.* Typhimurium (Figure [5](#F5){ref-type="fig"}) and *S.* Newport \[[@B41]\] provides further evidence that CRISPR-MVLST could serve as an appropriate alternative subtyping method.

Beyond the data shown here and in further evaluating the value of CRISPR-MVLST sequence typing, a recent study investigating *S.* Typhimurium isolates from a variety of animal sources showed an association of CRISPR-MVLST sequence types and resistance to antibiotics \[[@B40]\]. As part of that study, the most frequent TSTs were TST10 and TST42, both of which were found in this current study. TST10 was also the most frequent clinical sequence type seen in this study (16/86 isolates) but only two isolates were TST42.

Conclusion
==========

CRISPR-MVLST is a relatively new subtyping approach with limited studies conducted in *Salmonella* that demonstrate its utility \[[@B33],[@B34],[@B39]\]. Our data here add to this body of work by demonstrating its functionality in two highly prevalent clinical serovars. Investigation of several more outbreak strains using CRISPR-MVLST will elucidate the true capability of this subtyping method. Our data here show that CRISPR-MVLST can be used in concert with PFGE, as in the case of *S.* Heidelberg, or potentially as an independent subtyping method, as in the case of *S.* Typhimurium.

Methods
=======

Bacterial isolates and sample preparation
-----------------------------------------

A summary of all isolates analyzed in this study is listed in Table [5](#T5){ref-type="table"}. A total of 89 and 86 clinical isolates of *S.* Heidelberg and *S.* Typhimurium, respectively, were obtained from the Pennsylvania Department of Health. These isolates were selected systematically (isolates received closest to the 1^st^ and 15^th^ of each month from 2005 -- 2011 were selected) to represent an unbiased collection of human clinical isolates. PFGE-*XbaI* analysis of these isolates was conducted using standard protocols \[[@B7],[@B53]\]. All isolates were stored at -80°C in 20% glycerol. Isolates were grown overnight in 2 mL LB at 37°C in a shaking incubator. DNA was isolated using the Promega genomic DNA isolation kit, following the manufacturer's directions (Promega, Madison, WI). DNA samples were stored at -20°C prior to PCR analysis.

PCR amplification
-----------------

Primers for amplification of all four genomic loci are listed in Table [6](#T6){ref-type="table"}. PCR reactions were performed in a total volume of 25 μl: 1.5 μl template, 0.3 μl Taq (1.5 units; New England Bio Labs, Ipswich, MA), 0.2 μl 10 mM dNTPs, 1 μl of each 10 μM primer, 2.5 μl of 10× *Taq* buffer and 18.5 μl water. PCR conditions were as follows and the annealing temperatures (AT) are listed in Table [6](#T6){ref-type="table"}: initial denaturation step of 10 minutes at 94°C followed by 35 cycles of 1 minute at 94°C, 1 minute at AT and extension for 1 minute (*fimH* and *sseL*) or 1.5 minutes (CRISPR1 and CRISPR2) at 72°C; a final extension step was done at 72°C for 8 minutes. 5 μl of each PCR product was electrophoretically analyzed on a 1.2% agarose gel and the remaining reaction stored at -20°C.

###### 

List of primers used in this study for PCR amplification and sequencing of the four CRISPR-MVLST markers

   **Primer**   **Orientation**     **Primer sequence (5′-3′)**     **Annealing temp.**   **PCR**   **Sequencing**
  ------------ ----------------- --------------------------------- --------------------- --------- ----------------
   CRISPR1-5        Forward         TGAAAACAGACGTATTCCGGTAGATT             55.5              ✓            ✓
   CRISPR1-1        Reverse            CAGCATATTGACAAGGCGCT                  ✓               ✓     
   CRISPR2-3        Forward            ATTGTTGCGATTATGTTGGT                 57               ✓            ✓
   CRISPR2-1        Reverse            TCCAGCTCCCTTATGATTTT                  ✓                     
   CRISPR2-4        Reverse          GCAATACCCTGATCCTTAACGCCA                                             ✓
   CRISPR2-5        Reverse            CGACGAAATTAAAACCGAACT                                              ✓
   CRISPR2-6        Forward             CGGATTCCATGCGTTTTCA                                               ✓
   CRISPR2-7        Forward             CCGGCGAGGTCAATAAAA                                                ✓
   CRISPR2-8        Forward             TGACGCTGGTCTATACCG                                                ✓
   CRISPR2-9        Forward              GTGACGTCAGTGCCGAA                                                ✓
   CRISPR2-10       Reverse            CTCTTCGCACTCTCGATCAA                                               ✓
     fimH-1         Forward           AGGTGAACTGTTCATCCAGTGG               56.7              ✓            ✓
     fimH-2         Reverse            GCGGGCTGAACAAAACACAA                  ✓               ✓     
     sseL-1         Forward       AAAATCAGGTCTATGCCTGATTTAATATATC           60               ✓             
     sseL-2         Reverse           GGCTCTAAGTACTCACCATTACT                ✓                     
     sseL-3         Forward       ACCAGGAAACAGAGCAAAATGAATATATGT                                          ✓
     sseL-4         Forward         TTCTCTCGGTAAACTATCCTATTGGGC                                           ✓

DNA sequencing
--------------

PCR products were treated with 10 units of Exonuclease (New England Bio Labs, Ipswich, MA) and 1 unit of Antarctic alkaline phosphatase (New England Bio Labs, Ipswich, MA). The mixture was incubated for 40 minutes at 37°C to remove remaining primers and unincorporated dNTPs. The enzymes were inactivated by incubating the samples at 85°C for 15 minutes. Purified PCR products were sequenced at the Huck Institute's Nucleic Acid Facility at The Pennsylvania State University using 3' BigDye-labeled dideoxynucleotide triphosphates (v 3.1 dye terminators; LifeTechnoloties, Carlsbad, CA) and run on an ABI 3730XL DNA Analyzer, using ABI Data Collection Program (v 2.0). Data was analyzed with ABI Sequencing Analysis software (Version 5.1.1). The primers used for sequencing are listed in Table [6](#T6){ref-type="table"}. In total, four PCR reactions and eight sequencing reactions were conducted for each isolate being typed. Additionally, one internal sequencing reaction was required for 14/26 *S*. Typhimurium CRISPR2 alleles, due to the increased length of this locus. There were two alleles (only representing 2/86 *S.* Typhimurium isolates), 181 and 205, which required extra primers due to the presence of a duplicated region of the locus. The positions of these extra primers are shown in Additional file [1](#S1){ref-type="supplementary-material"}: Figure S[1](#F1){ref-type="fig"}. CRISPR2 alleles that were sequenced using more than two primers are indicated in Table [3](#T3){ref-type="table"}.

Sequence analysis and sequence type assignment
----------------------------------------------

Sequences were assembled and aligned using SeqMan and MegAlign, respectively (Lasergene 10, DNA Star, Madison, WI) and unique alleles were assigned a unique numerical designation. All sequences from this study were submitted as a batch to NCBI and the accession numbers (KF465853 - KF465929) are shown for each allele in Additional file [2](#S2){ref-type="supplementary-material"}. For each isolate the combination of allelic types at all four loci defines the serovar-designated sequence type (ST) (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}), with each unique allelic type assigned a different ST number. The presence of a SNP in any marker was sufficient to define a new allele. Analysis of CRISPR1 and CRISPR2 was performed using CRISPR-finder (<http://crispr.u-psud.fr/Server/>). We did not identify any SNPs within either CRISPR locus that defined any allele. Allelic differences occurred from deletion of one or more spacers, addition of a spacer or duplication/triplication of a spacer. Discriminatory power was calculated using the method described by Hunter and Gaston \[[@B54]\], with strains defined as either unique STs or unique PFGE patterns.

Relationships between TSTs were calculated using BURST (<http://www.pubmlst.org/analysis/>), with a group definition of n-1*.* Unique PFGE patterns, or pulsotypes, were defined by PulseNet, using the Dice coefficient with an optimization of 1.5% and a position tolerance of 1.5%. The difference of one band is sufficient to call two PFGE patterns different. PFGE dendrograms were generated using BioNumerics v. 6.6.

*S.* Typhimurium outbreak study
-------------------------------

A summary of 30 *S.* Typhimurium outbreak isolates that were obtained from the Pennsylvania Department of Health is listed in Table [4](#T4){ref-type="table"}. Ten of these isolates associated with an outbreak in 2004 (cluster 0411PAJPX-1c) where affected patients had been on a bus trip together, though no vector was ever identified. Another 10 isolates were linked to an outbreak in 2009 (cluster 0905PAJPX-1), which was associated with live poultry. The remaining 10 isolates represent sporadic case isolates, also from 2009 but were not associated with the 0905PAJPX-1 outbreak and thus served as controls. The isolates were cultured as described above.
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###### Additional file 1

**Location of CRISPR2 primers used for PCR and sequencing.** Representation of CRISPR2 spacers from three alleles (allele numbers shown on the left) with each unique spacer shown as a uniquely colored box. Regions of spacer duplication are indicated above the array with a black line. Allele 164 is the most frequent allele. Alleles 181 and 205 each only occurred in one isolate and given the length and the seven spacers that are duplicated (line 2), required five additional primers for sequencing. These were the only two isolates that required this many primers. The primers are indicated below the array. The PCR primers are shown in bold. With the exception of CR2-4, all were used for PCR and sequencing.

###### 

Click here for file

###### Additional file 2

Accession Numbers Table listing the accession numbers for all alleles identified in this study.

###### 

Click here for file
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